title: Permanent cerebral vessel occlusion via double ligature and transection.
abstract: Stroke is a leading cause of death, disability, and socioeconomic loss worldwide. The majority of all strokes result from an interruption in blood flow (ischemia). Middle cerebral artery (MCA) delivers a great majority of blood to the lateral surface of the cortex, is the most common site of human stroke, and ischemia within its territory can result in extensive dysfunction or death. Survivors of ischemic stroke often suffer loss or disruption of motor capabilities, sensory deficits, and infarct. In an effort to capture these key characteristics of stroke, and thereby develop effective treatment, a great deal of emphasis is placed upon animal models of ischemia in MCA. Here we present a method of permanently occluding a cortical surface blood vessel. We will present this method using an example of a relevant vessel occlusion that models the most common type, location, and outcome of human stroke, permanent middle cerebral artery occlusion (pMCAO). In this model, we surgically expose MCA in the adult rat and subsequently occlude via double ligature and transection of the vessel. This pMCAO blocks the proximal cortical branch of MCA, causing ischemia in all of MCA cortical territory, a large portion of the cortex. This method of occlusion can also be used to occlude more distal portions of cortical vessels in order to achieve more focal ischemia targeting a smaller region of cortex. The primary disadvantages of pMCAO are that the surgical procedure is somewhat invasive as a small craniotomy is required to access MCA, though this results in minimal tissue damage. The primary advantages of this model, however, are: the site of occlusion is well defined, the degree of blood flow reduction is consistent, functional and neurological impairment occurs rapidly, infarct size is consistent, and the high rate of survival allows for long-term chronic assessment.
authors.affiliation: Department of Neurobiology & Behavior, University of California, Irvine, Irvine, CA, USA.
authors.forename: Melissa F
authors.initials: MF
authors.lastname: Davis
authors.forename: Christopher
authors.initials: C
authors.lastname: Lay
authors.forename: Ron D
authors.initials: RD
authors.lastname: Frostig
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D020244:Infarction, Middle Cerebral Artery / Q000209:etiology*; D008026:Ligation / Q000379:methods; D008297:Male; D020768:Middle Cerebral Artery / Q000601:surgery*; D051381:Rats; D017207:Rats, Sprague-Dawley
references.citation: Stroke. 1989 Jan;20(1):84-91
references.pmid: 2643202
references.citation: J Cereb Blood Flow Metab. 1988 Aug;8(4):474-85
references.pmid: 3392112
references.citation: Brain. 2003 Jul;126(Pt 7):1650-9
references.pmid: 12805118
references.citation: Stroke. 1997 Jan;28(1):110-7
references.pmid: 8996498
references.citation: J Cereb Blood Flow Metab. 2010 Aug;30(8):1412-31
references.pmid: 20485296
references.citation: Muscle Nerve. 2001 Aug;24(8):1000-19
references.pmid: 11439375
references.citation: J Cereb Blood Flow Metab. 1989 Oct;9(5):589-96
references.pmid: 2674168
references.citation: Circulation. 2011 Feb 1;123(4):e18-e209
references.pmid: 21160056
references.citation: J Neurosci. 2011 Aug 10;31(32):11495-504
references.pmid: 21832179
references.citation: J Cereb Blood Flow Metab. 1999 Sep;19(9):997-1003
references.pmid: 10478651
references.citation: Stroke. 1982 Nov-Dec;13(6):855-9
references.pmid: 7147305
references.citation: Trends Neurosci. 1999 Sep;22(9):391-7
references.pmid: 10441299
references.citation: Stroke. 1998 Oct;29(10):2162-70
references.pmid: 9756599
references.citation: PLoS One. 2010 Jun 23;5(6):e11270
references.pmid: 20585659
references.citation: J Cereb Blood Flow Metab. 1986 Apr;6(2):195-202
references.pmid: 3958064
references.citation: Stroke. 2011 Mar;42(3):792-8
references.pmid: 21317269
references.citation: Nutrition. 2005 Jun;21(6):775-7
references.pmid: 15925305
references.citation: Transl Stroke Res. 2011 Dec;2(4):651-61
references.pmid: 24323685
references.citation: Pharmacol Biochem Behav. 2007 May;87(1):179-97
references.pmid: 17521716
references.citation: NeuroRx. 2005 Jul;2(3):396-409
references.pmid: 16389304
references.citation: Ann Neurol. 1985 May;17(5):497-504
references.pmid: 4004172
references.citation: J Cereb Blood Flow Metab. 1981;1(1):53-60
references.pmid: 7328138
references.citation: Stroke. 1993 Feb;24(2):294-7; discussion 297-8
references.pmid: 8421831
references.citation: J Neural Eng. 2006 Dec;3(4):L15-22
references.pmid: 17124326
references.citation: J Neurosci. 2008 Jan 30;28(5):1022-9
references.pmid: 18234880
references.citation: Stroke. 1995 Aug;26(8):1459-62
references.pmid: 7631353
references.citation: Stroke. 2003 Sep;34(9):2252-7
references.pmid: 12893948
references.citation: Stroke. 1995 Jun;26(6):1086-91; discussion 1091-2
references.pmid: 7762027
references.citation: J Am Heart Assoc. 2012 Aug;1(4):e001255
references.pmid: 23130160
references.citation: Stroke. 1994 Apr;25(4):808-13
references.pmid: 8160225
references.citation: J Neurosci Methods. 1996 Jan;64(1):19-23
references.pmid: 8869480
references.citation: Brain. 2000 May;123 ( Pt 5):940-53
references.pmid: 10775539
references.citation: Stroke. 2002 Aug;33(8):2025-31
references.pmid: 12154257
references.citation: Stroke. 1995 Sep;26(9):1655-7; discussion 1658
references.pmid: 7660413